Autologous hematopoietic SCT (auto-HSCT) can be curative for patients with germ cell tumors. Poor stem cell mobilization jeopardizes the ability to deliver this therapy. Herein, we describe a retrospective study examining safety and efficacy of plerixafor in combination with G-CSF for patients with germ cell tumors who had previously failed stem cell collection. Overall, 21 patients with germ cell tumors and previous mobilization failure were remobilized with G-CSF (10 mg/kg SC) and plerixafor (0.24 mg/kg SC) beginning the evening of day 4 of G-CSF treatment. Dosing of G-CSF and plerixafor was repeated until collection of X2 Â 10 6 CD34 þ cells/kg. Remobilization resulted in a median yield of 3.2 Â 10 6 CD34 þ cells/kg. A total of 17 (81%) patients collected X2 Â 10 6 and 9 (43%) patients collected X4 Â 10 6 CD34 þ cells/kg in a median of 2 (range 1 --3) and 3 (range 1 --4) days, respectively. In all, 16 (76%) patients proceeded to transplant; 8 (38%) received tandem transplants. There were no serious adverse events. In summary, the majority of patients with germ cell tumors who failed prior mobilization with growth factors ± chemotherapy were remobilized with plerixafor plus G-CSF facilitating at least one auto-HSCT. Use of plerixafor plus G-CSF can increase access of this potentially life-saving procedure to patients with high-risk germ cell tumors.
INTRODUCTION
High-dose chemotherapy with autologous hematopoietic SCT (auto-HSCT) has an important role in the management of patients with high-risk germ cell tumors. 1, 2 Collection of adequate numbers of hematopoietic stem cells is an important prerequisite for those patients who are candidates for this procedure. As it is currently common practice to perform sequential cycles of high-dose therapy, large numbers of hematopoietic stem cells are needed. Mobilized PBSCs are the preferred graft source for this procedure. However, the vast majority of patients with germ cell tumors that are candidates for auto-HSCT have been treated with multiple cycles of highly cytotoxic chemotherapy, thereby compromising the efficacy of PBSC mobilization with G-CSF. 3, 4 Plerixafor is a small-molecule bicyclam that selectively and reversibly inhibits the interaction between the chemokine receptor CXCR4 and stromal cell-derived factor 1. 5 --7 This results in release of hematopoietic progenitors from their BM niche into the peripheral blood. Plerixafor is approved for use with G-CSF to mobilize hematopoietic stem cells in patients with nonHodgkin's lymphoma and multiple myeloma. 8 --10 It is widely used in combination with G-CSF for both the initial stem cell mobilization attempts and for patients who have unsuccessfully mobilized using traditional approaches. In this retrospective analysis of data from a North American compassionate use protocol, we report the safety and efficacy of plerixafor in combination with G-CSF for mobilization of PBSCs in patients with germ cell tumors who have previously failed a stem cell mobilization attempt.
MATERIALS AND METHODS
This study retrospectively analyzed data from patients with germ cell tumors who participated in the plerixafor compassionate use program (CUP). 11 The plerixafor CUP evaluated the safety and efficacy of mobilization with plerixafor plus G-CSF in patients who were candidates for auto-HSCT but from whom insufficient cells were collected or in patients who, based on a low peripheral blood CD34 þ cell count following conventional therapy, were not considered by the physician to have a reasonable chance of sufficient stem cell collection. Inclusion criteria were an Eastern Cooperative Oncology Group performance status of 0 or 1, WBC count 42.5 Â 10 9 /L, ANC 41.5 Â 10 9 /L, platelet count 485 Â 10 9 /L, liver function test results otwo times the upper limit of normal, creatinine clearance 460 mL/min, and cardiac and pulmonary function sufficient for undergoing apheresis and transplantation. Furthermore, patients were to have recovered from all acute toxic effects of prior chemotherapy. Exclusion criteria comprised brain metastases, acute infection, active hepatitis B or C infection, fever (438 1C/100.4 1F), hypercalcemia (41 mg/dL above the upper limit of normal), and pregnancy. It should be noted that the CUP was designed in accordance with good clinical practice. However, as this program was focused on the treatment of individuals rather than an investigation designed to further drug development, the conduct of the CUP was not monitored at sites. Completion of case report forms and submissions were tracked via telephone and written contact with the site.
Mobilization protocol
The mobilization protocol consisted of s.c. G-CSF (10 mg/kg/day) administered on days 1 through 4 and plerixafor (0.24 mg/kg/day SQ) administered on the evening of day 4. Apheresis (processed blood volumes as per institutional standard) was initiated on the morning of day 5, approximately 10 to 11 h after the dose of plerixafor. Mobilization and apheresis continued until a minimum of 2 Â 10 6 CD34 þ cells/kg were collected.
Outcome measures
Outcome measures included CD34 þ cell collection yields after mobilization with plerixafor plus G-CSF, the ability to collect sufficient cells to proceed to transplantation, the number of patients who proceeded to transplantation, neutrophil and platelet engraftment after transplantation, graft durability and adverse events. Successful mobilization was defined as collection of a total X2 Â 10 6 CD34 þ cells/kg during therapy with plerixafor plus G-CSF. Collection of a CD34 þ cell dose in excess of the minimum threshold of 2 Â 10 6 /kg was left to the discretion of the managing physician. After transplantation, patients were monitored for neutrophil and platelet engraftment according to the local standard of care. Graft durability was defined as the maintenance of normal blood counts at 3, 6 and 12 months after transplantation, according to the following criteria: a platelet count of 450 Â 10 9 /L without transfusion for at least 2 weeks before the follow-up visit; a Hb level of X10 g/dL with no EPO or transfusions for at least 1 month before the follow-up visit; and an ANC of 41 Â 10 9 /L with no G-CSF for at least 1 week before the follow-up visit.
Documentation of adverse events
Adverse events occurring from the time of the first dose of plerixafor until 30 days after the last apheresis or until the first dose of myeloablative chemotherapy (whichever occurred first) were to be reported. Any serious adverse events occurring from the time of the first dose of plerixafor until 6 months after transplantation were also to be reported. All adverse events were graded in terms of severity and potential relationship to plerixafor; graft failure occurring up to 12 months after transplantation was considered a serious adverse event.
RESULTS

Patient characteristics
Of the 1047 patients in the CUP database, 21 adult patients had germ cell tumors and are included in this analysis. Patients had a median age of 35 years (range 20 --51). A total of 14 patients (67%) had a prior mobilization attempt with G-CSF alone, and 7 patients (33%) had a prior mobilization attempt using chemotherapy with G-CSF. With the previous mobilization attempt, 17 patients (81%) underwent apheresis that failed to yield a transplantable stem cell dose (median yield 1.35 (range 0.33 --2.1) Â 10 6 CD34 þ cells/kg). In all, 4 patients (19%) did not undergo apheresis due to low circulating CD34 þ cell levels (median 2.4 (range 0 --4.6) CD34 þ cells/mL) ( Table 1) .
Stem cell mobilization and transplantation outcomes After mobilization with G-CSF and plerixafor, the median CD34 þ cell collection for the 21 patients with germ cell tumors was 3.2 Â 10 6 cells/kg (range, 0.76 Â 10 6 --15.8 Â 10 6 cells/kg) ( Table 2 ). The minimum target (X2 Â 10 6 CD34 þ cells/kg) was collected from 17 (81%) patients in a median of 2 days (range, 1 --3 days). A stem cell dose of X4 Â 10 6 CD34 þ cells/kg (target for tandem transplant) was collected from nine patients (43%) in a median of 3 days (range 1 --4).
A total of 17 patients (81%) successfully collected a minimum CD34 þ cell dose of 2 Â 10 6 /kg. Three of these patients did not proceed to transplant due to death (n ¼ 1) or unknown reasons (n ¼ 2). A total of 16 (76%) patients proceeded to SCT (Table 2) . This includes two patients who did not collect X2 Â 10 6 CD34 þ cells/kg, but were transplanted with cells that were pooled from a previous collection. Eight patients (38%) underwent a second SCT procedure.
Neutrophil and platelet engraftment occurred in all patients. For patients undergoing the first stem cell transplant procedure, the median time to neutrophil engraftment was 11 days (range, 9 --18), and the median time to platelet engraftment was 20 days (range, 12 --48). For patients who underwent a second stem cell transplant procedure, the median time to neutrophil engraftment was 10.5 days (range, 9 --12), and the median time to platelet engraftment was 24 days (range, 12 --44) ( Table 2) . None of the patients experienced secondary graft failure. Toxicity Overall, 17 adverse events felt to be possibly, probably or definitely related to plerixafor were reported in eight (38%) patients with germ cell tumors. None of the events were classified as serious. One patient experienced chills, which were moderate in severity.
All other adverse events were mild and included diarrhea (n ¼ 3), nausea (n ¼ 2), injection site reactions (n ¼ 3), bone pain (n ¼ 2), chills (n ¼ 1), neck pain (n ¼ 1), lip swelling (n ¼ 1), abnormal dreams (n ¼ 1), blurred vision (n ¼ 1) and fatigue (n ¼ 1).
DISCUSSION
The data described in this report establish the efficacy of plerixafor for mobilization of PBSCs in patients with germ cell tumors who have failed a prior stem cell collection attempt. Plerixafor had a critical role in facilitating 76% of these heavily pretreated patients to proceed to at least 1 auto-HSCT. Of these, nine patients went on to a second auto-HSCT procedure.
While timing and patient selection for use of auto-HSCT in the treatment of high-risk germ cell tumors remains controversial, efficacy of the procedure has been firmly established. Multiple single center and registry-based studies targeting patients with metastatic germ cell tumors have found that the use of auto-HSCT appears to be a curative option.
1,2,12,13 Lorch et al. sampled data from a large international database and examined outcome of auto-HSCT as first salvage therapy after failure of cisplatin-based upfront therapy. Fifty percent of patients received a single autologous transplant and 50% received sequential autologous transplants. The authors found that auto-HSCT resulted in a 5-year OS that ranged from 89% in a very low-risk group to 27% in a very high-risk group. 2 The study included a retrospective comparison of auto-HSCT to conventional chemotherapy, and found that auto-HSCT may be superior to conventional salvage therapy for this patient population. Einhorn and colleagues reviewed outcomes of 184 consecutive patients at the University of Indiana who underwent auto-HSCT for high risk relapsed or refractory germ cell tumors. Like the Lorch study, all patients had failed prior cisplatin containing chemotherapy regimens. A total of 173 (94%) patients received tandem SCT. With a median follow-up of 4 years, 116 of the 184 patients (63%) were alive and disease-free. 1 Two important conclusions can be drawn from these data. First, for many patients with high-risk germ cell tumors, auto-HSCT provides an opportunity for potentially curative therapy. The second conclusion is that as a result of availability of highly active and efficacious salvage regimens for relapsed/refractory germ cell tumors, many autologous stem cell transplant candidates with germ cell tumor have been heavily pre-treated and thus likely to be poor mobilizers. The demonstrated activity of plerixafor for this patient population is reassuring, and will likely increase access to this treatment modality.
The data presented herein represent the largest series to date establishing the efficacy of plerixafor as a rescue for germ cell tumor patients with a suboptimal mobilization response to chemotherapy with G-CSF or G-CSF alone. The results confirm the observations of Kobold et al.
14 who report the results from Europe of plerixafor rescue in six patients who failed chemotherapy mobilization. Furthermore, the data are consistent with other studies demonstrating efficacy of plerixafor used in combination with G-CSF to rescue poor mobilizers with lymphoma and multiple myeloma. 11, 15 In this highly selected population of poor mobilizers with relapsed/refractory germ cell tumor, 43% of patients achieved the desired stem cell collection of X4 Â 10 6 CD34 þ cells/kg. As a collection goal of X4 Â 10 6 CD34 þ cells/kg was left to the discretion of the managing physician, it is possible that additional patients may have achieved this threshold with further apheresis sessions. This limited these patients to a single cycle of high-dose chemotherapy and autologous stem cell rescue. The data supporting the necessity of a tandem auto-HSCT for relapsed germ cell tumors is somewhat mixed. In an analysis of data from the Center for International Blood and Marrow Transplant Research, Lazarus et al. 16 found no difference in OS among recipients of planned single or tandem auto-HSCT. In contrast, Lorch et al. found a statistically significant difference in PFS and OS in patients receiving a single vs sequential auto-HSCT procedures (44% vs 55% Po0.001, 46% vs 61%, Po0.001, respectively). 2 However, the outcome of a single auto-HSCT remained superior to that of conventional dose chemotherapy suggesting a retained benefit of the high-dose treatment approach.
In conclusion, this study demonstrates the safety and efficacy of plerixafor in combination with G-CSF for collecting a transplantable stem cell dose in patients with germ cell tumors who experienced inadequate stem cell collection following the first mobilization attempt with traditional regimens.
